The AI week, distilled.
Week 42 · 2026
Non-Microsoft AI | 12–18 October 2026

Google expands Gemini access and previews connections to enterprise data

Google launched Gemini 4 Argon this week with introductory token pricing that ends after November. Its Lakehouse preview connects Gemini to data across existing platforms. A separate health-research announcement introduced a pipeline for designing new-to-nature enzymes.

01

Google launches Gemini 4 Argon with introductory pricing

Google launched Gemini 4 Argon on 13 October across its developer, enterprise and consumer services. Introductory API pricing is $2 per million input tokens and $10 per million output tokens.

  • Budget production workloads at the announced post-November rates of $4 per million input tokens and $20 per million output tokens.
  • Use a bounded pilot to test Czech-language accuracy and performance on your own business documents before selecting the model.
  • Evaluate the API and employee-facing Gemini services separately against your identity, data-handling and procurement requirements.
02

Google previews Gemini integration with its borderless Lakehouse

Google announced a preview connecting Gemini to enterprise data through its borderless Lakehouse. The announcement includes federated access to Databricks Unity Catalog and Snowflake Horizon.

  • For estates using Databricks or Snowflake, test federated access before budgeting a separate data migration for an AI project.
  • Assess the announced zero-copy integrations with SAP, Salesforce and Workday against the specific datasets your agents need.
  • Require security review of cross-cloud identities, agent permissions and data residency before exposing sensitive Czech or EU business data.
03

Google introduces an AI pipeline for enzyme design

Google introduced AlphaProtein Novo, a machine-learning pipeline for designing new-to-nature enzymes. Its broader health-research announcement covered applications including genetic-disease identification, drug repurposing and cancer detection.

  • Czech biotechnology teams should assess whether enzyme design addresses an existing research bottleneck before allocating an evaluation budget.
  • Treat the announcement as research rather than a procurement-ready enterprise product.
  • Healthcare buyers should require clinical validation and applicable regulatory clearance before using research outputs in patient care.